CDC Endorses Novavax COVID-19 Shot for Adults
U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax—a more traditional kind of vaccine, health officials said Tuesday.
Regulators authorized the nation’s first so-called protein vaccine against COVID-19 last week, but the final hurdle was a recommendation from the Centers for Disease Control and Prevention.
“If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated,” Dr. Rochelle Walensky, CDC’s director, said in a s...
Source: TIME: Health - July 20, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
Why You ’ ll Need to Get COVID-19 Boosters Again and Again
Several highly effective vaccines were developed at an unprecedented speed to combat the COVID-19 pandemic. During the phase 3 clinical trials, mRNA vaccines had vaccine efficacy of 94–95% in preventing symptomatic infections. After the rollout, real-world evidence showed that the mRNA vaccines provided ~90% effectiveness against infection. Then came the variants. The wave after wave of new variants, with ever-increasing transmissibility and capacity to escape existing immunity, challenge the ability of vaccines to prevent infection and transmission. The effectiveness of a primary series of mRNA vaccines (two doses) ...
Source: TIME: Health - July 19, 2022 Category: Consumer Health News Authors: Akiko Iwasaki and Albert Ko Tags: Uncategorized COVID-19 freelance Source Type: news
How COVID-19 Vaccines May Affect Periods
When clinical trials began testing the various COVID-19 vaccines, one question participants weren’t asked about was whether they experienced any changes to their menstrual cycles or unexpected bleeding after getting vaccinated.
Soon after the vaccines were rolled out to the public, however, people began talking to their doctors about what they were experiencing. Many had noticed that their periods had become heavier than normal. Initially, some clinicians were dismissive, write the authors of a new survey on the topic published in the journal Science Advances. “In media coverage, medical doctors and public heal...
Source: TIME: Health - July 18, 2022 Category: Consumer Health News Authors: Kyla Mandel Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Investor Update - July 18, 2022 Category: Pharmaceuticals Source Type: news
Roche launches innovative dual antigen and antibody diagnostic test supporting the fight to eliminate the hepatitis C virus
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.TheElecsys HCVDuo immunoassay enables significantly earlier diagnosis of active HCV infection, making it possible to get patients appropriate care sooner to stop both the disease progression and transmission.Basel, 18 July 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Elecsys ® HCV Duo immunoassay in countries that accept the CE Mark. Elecsys HCV Duo is the first available immunoassay that allows the simultaneous ...
Source: Roche Media News - July 18, 2022 Category: Pharmaceuticals Source Type: news
FREE CONTACT HOUR: JHSON Virtual Nursing Grand Rounds
p{
margin:10px 0;
padding:0;
}
table{
border-collapse:collapse;
}
h1,h2,h3,h4,h5,h6{
display:block;
margin:0;
padding:0;
}
img,a img{
border:0;
height:auto;
outline:none;
text-decoration:none;
}
body,#bodyTable,#bodyCell{
height:100%;
margin:0;
padding:0;
width:100%;
}
.mcnPreviewText{
display:none !important;
}
#outlook a{
padding:0;
}
img{
-ms-interpolation-mode:bicubic;
}
table{
mso-table-lspace:0pt;
mso-table-rspace:0pt;
}
.ReadMsgBody{
width:100%;
}
.ExternalClass{
width:100%;
}
p,a,li,td,blockquote{
...
Source: Johns Hopkins University and Health Systems Archive - July 13, 2022 Category: Nursing Source Type: news
Safety, Response to Inactivated COVID-19 Vaccine in Chronic HBV Safety, Response to Inactivated COVID-19 Vaccine in Chronic HBV
Are inactivated COVID-19 vaccines well tolerated in patients with chronic hepatitis B infection, and do they induce an effective antibody response?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 12, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
South Korea Approves First Domestically Developed COVID-19 Vaccine
SEOUL, South Korea — Health officials in South Korea on Wednesday approved the country’s first domestically developed COVID-19 vaccine for people 18 years or older, adding another public health tool in the fight against a prolonged pandemic.
In clinical trials involving some 4,000 participants in South Korea and five other countries, SK Bioscience’s two-dose SKYCovione vaccine appeared to be more effective than the broadly used AstraZeneca shots in building immunity against infections, officials at South Korea’s Food and Drug Safety Ministry said.
It isn’t immediately clear how officials will ...
Source: TIME: Health - June 29, 2022 Category: Consumer Health News Authors: Kim Tong-hyung / AP Tags: Uncategorized COVID-19 overnight wire Source Type: news
Wisconsin SeniorCare Program to Cover Vaccines Provided at Pharmacies
Gov. Tony Evers and the Wisconsin Department of Health Services (DHS) announce Wisconsin ’s SeniorCare Program has received approval from the Centers for Medicare& Medicaid Services (CMS) to cover certain vaccines that members receive in pharmacies. Vaccines covered include those that protect against shingles, tetanus, meningitis, and Hepatitis A and B. These vaccines are recommended by theAdvisory Committee on Immunization Practices...(see release) (Source: Wisconsin DHFS Press Releases)
Source: Wisconsin DHFS Press Releases - June 27, 2022 Category: Hospital Management Authors: millejcodn Source Type: news
Universal Hepatitis B Vaccination in Adults Aged 19-59 Years Universal Hepatitis B Vaccination in Adults Aged 19-59 Years
The ACIP has expanded the indicated age range for universal HepB vaccination to now include adults aged 19-59 years.Morbidity & Mortality Weekly Report (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 24, 2022 Category: Infectious Diseases Tags: Public Health & Prevention Journal Article Source Type: news
Reducing sexually transmitted infections [NG221], NICE (published 15th June 2022)
Guideline covers interventions to prevent sexually transmitted infections (STIs) in people from 16yrs age. It aims to reduce the transmission of all STIs, including HIV,& includes ways to help increase uptake of STI testing& vaccines for human papillomavirus& hepatitis A&B. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 16, 2022 Category: Consumer Health News Source Type: news
A Fourth COVID-19 Vaccine, From Novovax, Passed a Key Stage in the Authorization Process
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the protein vaccine made by latecomer Novavax as the nation’s fourth coronavirus shot for adults. It’s made with more conventional technology than today’s dominant Pfizer and Moderna shots and the lesser-used Johnson & Johnson option.
Novavax shots are already available in Australia, Canada, parts of Europe and multiple other countries, either for initial va...
Source: TIME: Health - June 8, 2022 Category: Consumer Health News Authors: LAURAN NEERGAARD / AP Tags: Uncategorized COVID-19 healthscienceclimate wire Source Type: news
FDA Advisers Back a New COVID-19 Vaccine, Made By Novavax
American adults who haven’t yet gotten vaccinated against COVID-19 may soon get another choice, as advisers to the Food and Drug Administration on Tuesday backed a more traditional type of shot.
Next, the FDA must decide whether to authorize the vaccine made by latecomer Novavax, a protein vaccine that’s made with a more conventional technology than today’s U.S. options.
Novavax shots are already used in Australia, Canada, parts of Europe and dozens of other countries. But U.S. clearance is a key hurdle for the Maryland-based company.
FDA’s vaccine chief Dr. Peter Marks said another choice in the U....
Source: TIME: Health - June 7, 2022 Category: Consumer Health News Authors: Lauran Neergaard / AP Tags: Uncategorized COVID-19 wire Source Type: news
FDA advisers recommend authorizing Novavax coronavirus vaccine
The Novavax vaccine is a protein vaccine, a more traditional technology found in other commonly used immunizations such as hepatitis B and influenza. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - June 7, 2022 Category: Consumer Health News Authors: Carolyn Y. Johnson Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
